article thumbnail

Market cap growth surges for over half of the top biopharmaceutical companies in 2022

Pharmaceutical Technology

The 13 top players experienced significant growth over 2022 despite the decline in demand for COVID-19 vaccines and therapeutics, as well as uncertainty surrounding pricing due to the newly passed Inflation Reduction Act in the US. billion on Dec 31, 2022. Merck & Co. Merck & Co. billion to $281.3 to $365.84.

article thumbnail

2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward

ISPE

2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward. Wed, 11/02/2022 - 07:32. 2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward. 2 November 2022. Pfizer “cleared runway to allow for large-scale vaccine manufacturing before we had a product!” iSpeak Blog.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Deep Dive: Digital Health 2022

pharmaphorum

Frontiers Health 2022. Influencer culture has well and truly taken over the internet, with numerous benefits on offer for pharmaceutical companies in the healthcare influencer space. Company profile: Vinehealth. Case study: Syneos Health and VBI Vaccines. Read Deep Dive: Digital Health 2022 in full.

article thumbnail

Deep Dive: Oncology 2022

pharmaphorum

Read on to find out about reaching the gold standard of lung cancer screening, the promise of therapeutic cancer vaccines, why diversity is essential in oncology trials, and much more. Realising the promise of cancer vaccines. ASCO 2022: Checkpoint inhibitors, Enhertu in spotlight. Read Deep Dive: Oncology in full.

article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment.

Vaccines 134
article thumbnail

The Pandemic Treaty and the opportunity to end ‘vaccine apartheid’

pharmaphorum

Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.

article thumbnail

The future of RNA-based Therapeutics  and Vaccines: Introducing advanced, Unrivalled Treatment Approaches

Roots Analysis

In this context, several industry players have demonstrated high inclination towards supporting and advancing the development of next generation RNA-based therapeutics, vaccine and technologies. The below given figure provides an illustrative summary of the benefits of next generation RNA-based vaccines and RNA-based therapeutics market.